ADAP Adaptimmune Therapeutics ADS

Adaptimmune to Present First Preclinical Data from its HLA-independent TCR (HiT) Platform at ASGCT

Adaptimmune to Present First Preclinical Data from its HLA-independent TCR (HiT) Platform at ASGCT

PHILADELPHIA and OXFORDSHIRE, United Kingdom, April 27, 2021 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, will report initial preclinical data from its HLA Independent TCR (HiT) targeting mesothelin, being co-developed with Astellas, during a poster presentation at the American Society for Cell and Gene Therapy (ASGCT) meeting. Abstracts were published online today, and data will be updated during the conference.

  • Abstract Title: In vitro selection and engineering of a human leukocyte antigen-independent T-cell receptor recognizing human mesothelin (Abstract # 641)
  • Poster Presentation: Tuesday May 11, 2021 8:00 a.m. - 10:00 a.m. EDT during the Cancer - Immunotherapy, Cancer Vaccines Session

About Adaptimmune

Adaptimmune is a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapy products for people with cancer. The Company’s unique SPEAR (Specific Peptide Enhanced Affinity Receptor) T-cell platform enables the engineering of T-cells to target and destroy cancer across multiple solid tumors.

Forward-Looking Statements

This release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA). These forward-looking statements involve certain risks and uncertainties. Such risks and uncertainties could cause our actual results to differ materially from those indicated by such forward-looking statements, and include, without limitation: the success, cost and timing of our product development activities and clinical trials and our ability to successfully advance our TCR therapeutic candidates through the regulatory and commercialization processes. For a further description of the risks and uncertainties that could cause our actual results to differ materially from those expressed in these forward-looking statements, as well as risks relating to our business in general, we refer you to our Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on February 25, 2021 and our other SEC filings. The forward-looking statements contained in this press release speak only as of the date the statements were made and we do not undertake any obligation to update such forward-looking statements to reflect subsequent events or circumstances.

Adaptimmune Contacts:

Media Relations:

Sébastien Desprez — VP, Communications and Investor Relations

T: 3

M: 6

Investor Relations:

Juli P. Miller, Ph.D. — Senior Director, Investor Relations

T:

M:



EN
27/04/2021

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Adaptimmune Therapeutics ADS

Adaptimmune Therapeutics Plc: 5 directors

Five Directors at Adaptimmune Therapeutics Plc sold 133,839 shares at between 0.575USD and 0.582USD. The significance rating of the trade was 55/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's direct...

Maria Vara ... (+2)
  • Maria Vara
  • Oscar Haffen Lamm

End of coverage

From 5th February, we will no longer include in our research universe:Adaptimmune, ALK, argenx, Autolus, Cellectis, Galapagos, Hansa Biopharma, Heidelberg Pharma, Immatics, Immunocore, Ipsen, Moonlake Immunotherapeutics, Pharvaris, UCB, Vivoryon Therapeutics, Zealand Pharma, Nicox, GenSight Biologi

Alex Cogut
  • Alex Cogut

Coverage update

Given team and strategy changes, Alex Cogut is now assuming coverage of Achilles Therapeutics, Adaptimmune Therapeutics, Autolus, Calliditas, Cellectis, Galapagos, GenSight, Hansa Biopharma, Heidelberg Pharma, Immunocore, Innate Pharma, Sesorion and ValerioWe drop coverage of Celyad Oncology BioNte

Ingird Gafanhão ... (+2)
  • Ingird Gafanhão
  • Oscar Haffen Lamm

Conference updates: takeaways from ASCO and ISCT

We wrap up the past conference-filled weeks with a summary of the main takeaways from our coverage. From the International Society for Cell & Gene Therapy (ISCT) meeting, we point out i) Cellectis preclinical updates, and ii) a KOL dinner we hosted with Dr Bruce Levine discussing how to improve

Healthcare Team ... (+2)
  • Healthcare Team
  • Ingird Gafanhão

Transfer of coverage

from 1st June the cover of the following companies will be transferred to Ingrid GafanhaoADAPTIMMUNE THERAPEUTICSBIONTECHHEIDELBERG PHARMAIMMATICSIMMUNOCORE HOLDINGSINNATE PHARMAONXEOOSE IMMUNOTRANSGENE

ResearchPool Subscriptions

Get the most out of your insights

Get in touch